Lifeloc Technologies, INC

Lifeloc Technologies announced the resignation of its auditor due to a business sale and the approval of amended articles of incorporation at its annual meeting.

Lifeloc Technologies announced first quarter 2026 results, showing a slight revenue increase and a reduced net loss, alongside a significant development milestone for its SpinDetect drug analyzer.

Lifeloc Technologies has entered into a $500,000 promissory note with its CFO to fund the development of its SpinDetect product.

Lifeloc Technologies announced a 6% increase in 2025 revenue to $9.027 million, alongside a higher net loss of $2.470 million primarily due to a non-cash deferred tax valuation allowance.

Lifeloc Technologies, Inc. announced its third quarter 2025 financial results, reporting increased revenue but a wider net loss driven by R&D investments in its SpinDetect drug analyzer.

Lifeloc Technologies, Inc. has entered into a definitive merger agreement to acquire Electronic Systems Technology, Inc., making ELST a wholly-owned subsidiary.

Lifeloc Technologies reported a 1% increase in Q1 2026 revenue to $2.29 million, with a narrowed net loss of $152,713, driven by improved gross profit margins.

Lifeloc Technologies reports increased net losses for Q3 and the nine months ended September 30, 2025, driven by higher operating expenses and interest costs, despite modest revenue growth, as it invests heavily in its SpinDetect drug analysis system and pursues a merger with ELST.

Lifeloc Technologies reported increased net losses for Q2 and the first half of 2025, driven by declining product sales and higher interest expenses, despite ongoing investment in its SpinDx drug detection technology.

Lifeloc Technologies saw a 6% increase in product sales for Q1 2025 compared to Q1 2024, while continuing development of its SpinDx drug detection technology.

Lifeloc Technologies experienced a decrease in revenue and a net loss in Q3 2024, primarily due to reduced product sales and increased research and development expenses.

Lifeloc Technologies experienced a net loss in Q2 2024 due to increased research and development expenses, despite a slight increase in product sales.

Lifeloc Technologies, Inc. reported a significantly increased net loss for fiscal year 2025, driven by strategic investments in its SpinDetect platform and higher interest expenses, despite a modest revenue increase.

Lifeloc Technologies experienced a net loss in fiscal year 2024, primarily due to decreased product sales and increased research and development expenses related to the SpinDx project.

Lifeloc Technologies achieved profitability in 2023, marking a significant turnaround from the previous year's losses, driven by increased product sales and strategic investments in research and development.

Director Michael Kornelsen acquired 100 shares of Lifeloc Technologies common stock at $2.50 per share.

Lifeloc Technologies CEO Wayne Willkomm acquired 1,300 shares of common stock, increasing his direct beneficial ownership.

Michelle Heim, Controller at Lifeloc Technologies, reports the late filing of Form 4 due to inadvertently unreported stock option exercise and sale transactions on February 28, 2025.

Michelle Heim, Controller of Lifeloc Technologies, reports a late filing for a stock option transaction that occurred in March 2021.

Wayne Willkomm, CEO and President of Lifeloc Technologies, exercised stock options and amended a previous filing to correct the number of securities beneficially owned.

Wayne Willkomm, CEO and President of Lifeloc Technologies, reports a delayed filing for a stock option grant received on March 13, 2021.

Lifeloc Technologies announces its 2026 Annual Meeting of Shareholders to vote on director elections, auditor ratification, and corporate governance amendments.

LifeLoc Technologies refiles its definitive proxy statement to include Inline eXtensible Business Reporting Language (XBRL) data tagging.

Lifeloc Technologies will hold its annual shareholder meeting on June 4, 2025, to elect directors and ratify the appointment of its independent public accountants.

Lifeloc Technologies will hold its annual shareholder meeting on June 19, 2024, to elect directors and ratify the appointment of its independent public accountants.

EDCO Partners LLLP and its general partner, Vern D. Kornelsen, have filed a Schedule 13D revealing a combined beneficial ownership of 77.54% of Lifeloc Technologies, correcting a previous filing oversight.